Cancer is the most common cause of death in adult dogs. Many features of spontaneously developing tumors in pet dogs contribute to their potential utility as a human disease model. These include similar environmental exposures, similar clonal evolution as it applies to important factors such as immune avoidance, a favorable body size for imaging and serial biopsy, and a relatively contracted time course of disease progression, which makes evaluation of temporal endpoints such as progression free or overall survival feasible in a comparatively short time frame. These criteria have been leveraged to evaluate novel local therapies, demonstrate proof of tumor target inhibition or tumor localization, evaluate potential antimetastatic approaches, and assess the efficacy, safety and immune effects of a variety of immune-based therapeutics. Some of these canine proof of concept studies have been instrumental in informing subsequent human clinical trials. This review will cover key aspects of clinical trials in dogs with spontaneous neoplasia, with examples of how these studies have contributed to human cancer therapeutic development.

+More

tumor target inhibition clinical environmental clonal evolution cancer therapeutic development progression free overall survival temporal endpoints immune

Douglas H. Thamm,Douglas H. Thamm,Douglas H. Thamm,.Canine Cancer: Strategies in Experimental Therapeutics. 9 (),.

Douglas H. Thamm,Douglas H. Thamm,Douglas H. Thamm,"Canine Cancer: Strategies in Experimental Therapeutics" 9

Douglas H. Thamm,Douglas H. Thamm,Douglas H. Thamm,"Canine Cancer: Strategies in Experimental Therapeutics"